Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,937 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Follow-Up Questions
BIOVF 주식의 가격 성능은 어떻습니까?
BIOVF의 현재 가격은 $30.04이며, 전 거래일에 decreased 0% 하였습니다.
Swedish Orphan Biovitrum AB (publ)의 주요 사업 주제나 업종은 무엇입니까?
Swedish Orphan Biovitrum AB (publ)은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Swedish Orphan Biovitrum AB (publ)의 시가총액은 얼마입니까?
Swedish Orphan Biovitrum AB (publ)의 현재 시가총액은 $10.7B입니다
Swedish Orphan Biovitrum AB (publ)는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 17명의 분석가가 Swedish Orphan Biovitrum AB (publ)에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 9명의 매수, 4명의 보유, 1명의 매도, 그리고 5명의 강력한 매도를 포함합니다
